All Title Author
Keywords Abstract

华西医学  2014 

硼替佐米联合地塞米松和沙利度胺治疗老年多发性骨髓瘤疗效观察

DOI: 10.7507/1002-0179.20140182, PP. 603-606

Keywords: 老年,多发性骨髓瘤,硼替佐米,化学疗法

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的 观察硼替佐米联合地塞米松和沙利度胺(T-VD)方案治疗老年多发性骨髓瘤患者的有效性和安全性。方法 2009年1月-2013年6月共纳入收治的54例多发性骨髓瘤患者,年龄均>60岁,根据临床使用的不同化学疗法(化疗)方案分为T-VD组和T-VAD组,其中T-VD组25例,T-VAD组29例,T-VAD组采用长春新碱+蒽环类+地塞米松+沙利度胺化疗方案治疗,化疗至少2个周期后评价疗效及不良反应。结果 T-VD组总有效率(OR)为84.0%,其中获得完全缓解(CR)+非常好的部分缓解(VGPR)共计6例(24.0%);T-VAD组OR为48.3%,其中获得CR+VGPR共计1例(3.4%),T-VD组OR明显高于T-VAD组(χ2=7.513,P<0.05)。主要不良反应有乏力、恶心、呕吐、骨髓抑制、心脏毒性、周围神经病变;T-VAD组恶心、呕吐反应较T-VD组发生率高(χ2=5.794,P<0.05)。结论 T-VD治疗方案对于老年多发性骨髓瘤患者具有良好的疗效和安全性,建议开展深入研究和推广应用。

References

[1]  [ 5 ] Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma[J]. Leukemia, 2006, 20(9): 1467-1473.
[2]  [ 1 ] Rossi M, Di Martino MT, Morelli E, et al. Molecular targets for the treatment of multiple myeloma[J]. Curr Cancer Drug Targets, 2012, 12(7): 757-767.
[3]  [ 2 ] Schecter J, Lentzsch S. Multiple myeloma: defining the high-risk patient and determining the optimal treatment strategy[J]. Curr Hematol Malig Rep, 2013, 8(4): 277-283.
[4]  [ 3 ] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 232-235.
[5]  [ 4 ] Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15): 3412-3420.
[6]  [ 6 ] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[7]  [ 7 ] 黄仲夏. 多发性骨髓瘤的诊治进展[J]. 临床药物治疗杂志, 2013, 9(5): 4-7.
[8]  [ 8 ] Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2013, 88(3): 226-235.
[9]  [ 9 ] Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360.
[10]   Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J]. Cancer Cell Int, 2005, 5(1): 18.
[11]   Roccaro AM, Vacca A, Ribatti D, et al. Bortezomib in the treatment of cancer[J]. Recent Pat Anticancer Drug Discov, 2006, 1(3): 397-403.
[12]   Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications[J].Blood, 2003, 101(6): 2377-2380.
[13]   Sonneveld P, Schmidt-Wolf IG, Van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phaseⅢ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30(24): 2946-2955.
[14]   Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study[J]. Lancet, 2010, 376(9758): 2075-2085.
[15]   Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study[J]. Cancer, 2010, 116(13): 3143-3151.
[16]   Reeder CB, Reece DE, Kukreti V, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma[J]. Blood, 2010, 115(16): 3416-3417.
[17]   Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phaseⅢ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal